Okyo Pharma - Crunchbase Company Profile & Funding

Q: Where is Okyo Pharma's headquarters?

Okyo Pharma is located in London, England, United Kingdom.

Q: When was the last funding round for Okyo Pharma?

Okyo Pharma closed its last funding round on obfuscated from a Post-IPO Equity round.

Q: How much funding has Okyo Pharma raised to date?

Okyo Pharma has raised obfuscated.

Overview

Okyo Pharma

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Events

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About Okyo Pharma

CB Rank

118161

Okyo Pharma focuses on novel GPCR based therapeutics for eye diseases of high unmet need and non-opioid analgesics for chronic pain.

Founded

obfuscation

Public

Post-IPO Equity

London, England, United Kingdom

1-10

www.okyopharma.com/

Biotechnology

Health Care

Medical

Pharmaceutical

Funding Rounds

Post-IPO Equity

OBF

obfuscation

Grant

OBF

obfuscation

Post-IPO Debt

OBF

obfuscation

Key People

Gary Jacob: Chief Development Officer
Past Role: Okyo Pharma, Chief Executive Officer
Robert Dempsey: Chief Executive Officer
Past Role: Ashvattha Therapeutics, Interim Chief Executive Officer

Details

Legal Name

OKYO Pharma, Limited

Operating Status

Active

Stock Symbol

NASDAQ:OKYO

Company Type

For Profit

About the Company

Okyo Pharma focuses on novel GPCR based therapeutics for eye diseases of high unmet need and non-opioid analgesics for chronic pain.

Phone Number

+44 0207-495-2379

Contact Email

info@okyopharma.com

Predictions & Insights

Growth Insight

See this Growth Insight

Okyo Pharma is

Lorem

to be growing

Top Contributing Factors

Recently Raised Funding

Products & Services

Urcosimod (OK-101)

A lipidated chemerin peptide agonist targeting the ChemR23 GPCR to reduce inflammation and neuropathic pain in ocular diseases such as dry eye disease and neuropathic corneal pain.

OK-201

A non-opioid analgesic drug candidate targeting the MAS-Related G Protein-coupled Receptor (MRGPR) to reduce ocular neuropathic pain.

Research & Development

Okyo Pharma is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated

...

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Post-IPO Equity - Okyo Pharma	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Okyo Pharma	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Okyo Pharma	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Okyo Pharma	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Okyo Pharma	—	obfuscated obfuscation	—	Post-IPO Equity

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Post-IPO Equity - Okyo Pharma	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Okyo Pharma	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Okyo Pharma	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Okyo Pharma	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Okyo Pharma	—	obfuscated obfuscation	—	Post-IPO Equity